IO Biotech (IOBT) Price & Analysis

Compare

452 Followers

IOBT Stock Chart & Stats

$0.81

-$0.03(-3.11%)

At close: Jan 08 4:00 PM EST

$0.81

-$0.03(-3.11%)

Day’s Range― - ―

52-Week Range$0.32 - $2.79

Previous CloseN/A

Volume57.25K

Average Volume (3M)894.60K

Market Cap

$61.16M

Enterprise Value$11.76M

Total Cash (Recent Filing)$30.66M

Total Debt (Recent Filing)$1.46M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding71,948,845

10 Day Avg. Volume930,258

30 Day Avg. Volume894,603

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.29

Price to Sales (P/S)0.00

P/FCF Ratio-0.74

Enterprise Value/Market Cap0.19

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-12.92

Enterprise Value/Ebitda-0.13

Forecast

1Y Price Target

$1.70

Price Target Upside109.88% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)-1.09

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe trial demonstrated a median PFS of 19.4 months in combination therapy versus 11.0 months with pembrolizumab alone, showing an impressive 8+ month benefit in median PFS.

Regulatory ProgressThe management intends to file for approval by the end of the year and is seeking Priority Review, indicating a proactive strategy despite challenges.

Strategic Regulatory MovesCompany plans to meet with FDA on Ph3 trial design for Cylembio in advanced.

Bears Say

Financial ConstraintsThe company will need to either raise additional capital, partner, or out-license Cylembio to advance the new Phase 3 trial as it currently has a cash runway through 1Q26.

Operational ChallengesAnnounces restructuring including a 50% head count reduction.

Regulatory DelaysThe FDA does not recommend that the company submit a BLA for Cylembio as the trial narrowly missed statistical significance for its primary endpoint.

IO Biotech News

IO Biotech Announces Resignation of Chief Accounting Officer

The latest update is out from IO Biotech ( ($IOBT) ). On November 17, 2025, IO Biotech, Inc....

23d ago

IOBT

IO Biotech’s Q3 2025: Progress in Cancer Vaccine Trials

Io Biotech, Inc. ( ($IOBT) ) has released its Q3 earnings. Here is a breakdown of the information...

26d ago

IOBT

IO Biotech Presents at Jefferies Global Healthcare Conference

IO Biotech ( ($IOBT) ) has provided an announcement. IO Biotech, Inc. announced its participation in the Jefferies...

26d ago

IOBT

IO Biotech’s Hold Rating Amid Financial and Regulatory Uncertainty

Analyst Michael Ulz of Morgan Stanley reiterated a Hold rating on IO Biotech, retaining the price target of...

29d ago

IOBT

IO Biotech reports Q3 EPS (13c) vs (36c) last year

“We remain keenly focused on our mission to develop novel, immune-modulatory, off-the-shelf cancer therapies for the treatment of...

1M ago

IOBT

IO Biotech presents pre-clinical data on IO112, IO170

IO Biotech (IOBT) announced new pre-clinical data for IO Biotech’s next vaccine candidate, IO112, and additional candidate, IO170,...

1M ago

IOBT

IO Biotech price target lowered to $3 from $10 at Piper Sandler

Piper Sandler lowered the firm’s price target on IO Biotech (IOBT) to $3 from $10 and keeps an...

2M ago

IOBT

IO Biotech reports expanded Cylembio results

IO Biotech (IOBT) presented detailed results from its global Phase 3 trial of Cylembio, in combination with Merck’s...

2M ago

MRK

IOBT

IO Biotech downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded IO Biotech (IOBT) to Equal Weight from Overweight with a price target of 39c, down...

3M ago

IOBT

Hold Rating for IO Biotech Amid Regulatory and Financial Challenges

In a report released yesterday, Michael Ulz from Morgan Stanley downgraded IO Biotech to a Hold, with a...

3M ago

IOBT

IO Biotech downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded IO Biotech (IOBT) to Hold from Buy without a price target after the FDA recommended...

3M ago

IOBT

IO Biotech downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar downgraded IO Biotech (IOBT) to Neutral from Buy with no price target Published...

3M ago

IOBT

H.C. Wainwright downgrades IO Biotech after FDA recommends another Phase 3 trial

As previously reported, H.C. Wainwright downgraded IO Biotech (IOBT) to Neutral from Buy with no price target after...

3M ago

IOBT

FDA Recommends Against IO Biotech’s Cylembio Application

IO Biotech ( ($IOBT) ) has shared an announcement. On September 25, 2025, IO Biotech‘s Board of Directors...

3M ago

IOBT

IOBT FAQ

What was IO Biotech’s price range in the past 12 months?

IO Biotech lowest stock price was $0.32 and its highest was $2.79 in the past 12 months.

What is IO Biotech’s market cap?

IO Biotech’s market cap is $61.16M.

When is IO Biotech’s upcoming earnings report date?

IO Biotech’s upcoming earnings report date is May 19, 2026 which is in 156 days.

How were IO Biotech’s earnings last quarter?

IO Biotech released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.194.

Is IO Biotech overvalued?

According to Wall Street analysts IO Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IO Biotech pay dividends?

IO Biotech does not currently pay dividends.

What is IO Biotech’s EPS estimate?

IO Biotech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does IO Biotech have?

IO Biotech has 71,948,845 shares outstanding.

What happened to IO Biotech’s price movement after its last earnings report?

IO Biotech reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went up 2.469%.

Which hedge fund is a major shareholder of IO Biotech?

Currently, no hedge funds are holding shares in IOBT

IO Biotech Stock Smart Score

Neutral

Fundamentals

Return on Equity

-240.48%

Trailing 12-Months

Asset Growth

-55.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IO Biotech

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech (IOBT) Earnings & Revenues

Historic Earnings Reports

IOBT Stock 12 Month Forecast

Average Price Target

$1.70

▲(109.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.1907692307692308,1.3415384615384616,1.4923076923076923,1.643076923076923,1.7938461538461539,1.9446153846153846,2.0953846153846154,2.246153846153846,2.396923076923077,2.5476923076923077,2.6984615384615385,2.8492307692307692,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.0907692307692307,1.1415384615384616,1.1923076923076923,1.2430769230769232,1.2938461538461539,1.3446153846153845,1.3953846153846152,1.4461538461538461,1.496923076923077,1.5476923076923077,1.5984615384615384,1.649230769230769,{"y":1.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,0.99,0.9400000000000001,0.89,0.8400000000000001,0.79,0.74,0.69,0.64,0.5900000000000001,0.54,0.49,0.43999999999999995,{"y":0.39,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.55,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >